Alnylam Pharmaceuticals
ALNYAlnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Alnylam Pharmaceuticals
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/5/2026 | Sell | Fitzgerald, Kevin Joseph | CSO & EVP, Head of Research | $324.0 | $213,177 |
| 3/5/2026 | Sell | Garg, Pushkal | EVP Chief R&D | $324.1 | $778,812 |
| 3/4/2026 | Sell | Fitzgerald, Kevin Joseph | CSO & EVP, Head of Research | $322.4 | $204,508 |
| 3/4/2026 | Sell | Tanguler, Tolga | EVP, Chief Commercial Officer | $322.4 | $745,983 |
| 3/4/2026 | Sell | Poulton, Jeffrey V. | EVP, Chief Financial Officer | $322.4 | $797,349 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)